Status:
COMPLETED
Impact of Standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke
Lead Sponsor:
Charite University, Berlin, Germany
Collaborating Sponsors:
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Conditions:
Stroke
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Investigator-initiated prospective randomized multicentre study to uncover the true burden of paroxysmal atrial fibrillation in a representative population of acute stroke patients without known atria...
Eligibility Criteria
Inclusion
- Acute ischemic stroke or transitory ischemic attack (with clinical deficit on enrolment or MRI detected acute brain lesion on admission)
- Age ≥ 18 years
- Written or oral informed consent
- Stroke unit admission within 72 hours after stroke onset
- Start of standardized prolonged ECG monitoring within 24 hours after admission to the stroke unit
- Willingness to take part in the planned follow up examinations
Exclusion
- Known atrial fibrillation
- Atrial fibrillation detected by ECG on admission
- Atrial fibrillation detected prior study enrollment on the stroke unit
- Life expectancy \< 1 year (before actual stroke)
- Life expectancy \< 1 month (after actual stroke)
- Indication for oral anticoagulation other than atrial fibrillation (e.g. mechanical heart valve)
- Severity level according National Institute of Health Stroke Scale (NIHSS) score \> 22
- Participation in an interventional trial
Key Trial Info
Start Date :
December 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2020
Estimated Enrollment :
3470 Patients enrolled
Trial Details
Trial ID
NCT02204267
Start Date
December 1 2014
End Date
October 1 2020
Last Update
November 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Charité Universitaetsmedizin Berlin
Berlin, Germany, 12203